Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It includes details about the product, its registration, intended use, and potential impact on the company. The document is relatively short (1325 characters) and does not contain financial statements, detailed financial performance, or regulatory certifications. It is an announcement of a regulatory approval related to product registration rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-17 Chinese
圣湘生物科技股份有限公司关于实际控制人兼董事长提议增强股东分红回报暨落实公司2024年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a proposal by the actual controller and chairman to enhance shareholder dividend returns and implement a 2024 action plan for improving quality, efficiency, and returns. It discusses future dividend distribution plans and commitments but does not contain actual financial statements or detailed financial results. The document is relatively short (1192 characters) and serves as a formal announcement of a proposal related to dividends rather than the dividend payment notice itself. It does not fit the criteria for a Notice of Dividend Amount (DIV) because it does not specify exact dividend amounts or payment dates for a declared dividend. Instead, it is an announcement of a proposal and plan related to dividends and shareholder returns. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-29 Chinese
圣湘生物科技股份有限公司关于参加湖南辖区2024年度投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about participation in an investor online collective reception day event organized by regulatory and industry bodies. It mentions the date and method of the event and invites investors to participate. There is no financial data, no report attached or published, no voting results, no management changes, no earnings or audit information. The document is a regulatory announcement about an investor event, not a report or financial filing. Therefore, it fits best under Regulatory Filings (RNS).
2024-09-27 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It details the product registration, its intended use, the impact on the company, and risk warnings. There are no financial statements, no mention of annual or quarterly reports, no earnings data, no management or board changes, no voting results, no merger or acquisition activity, and no regulatory certifications or attestations. The document is an official announcement about a regulatory approval related to product registration, which fits best under general regulatory announcements. It is not a report or financial filing but a regulatory disclosure about product certification.
2024-09-25 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司差异化权益分派事项之法律意见书
Regulatory Filings
2024-09-19 Chinese
圣湘生物科技股份有限公司2024年半年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an "权益分派实施公告" which translates to "Implementation Announcement of Equity Distribution" for the 2024 half-year period. It details the dividend distribution plan, including cash dividend per share, relevant dates (record date, ex-dividend date, payment date), and tax treatment for different shareholder categories. It also mentions the approval of the distribution plan at the 2024 first extraordinary shareholders meeting. The document is an announcement of the dividend amount and payment details rather than a full financial report or annual/interim report. The length is about 3,295 characters, which is relatively short and consistent with an announcement. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV).
2024-09-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.